- Press Releases
- Events & Presentations
- Corporate Governance
- Shareholder & Stock Info
- Analyst Coverage
- Financial Reports
- Financial calendar
- Secured Rights issue 2018
- Secured Rights issue 2017
Scientific Advisory Board
The scientific advisory board of Immunicum consist of members with broad competence and extensive experience from the Life Science-industry. The Scientific Advisory Board functions as an advisory body to the company’s Board of Directors and to the scientific committee. A presentation of the members in Scientific Advisory Boards follows below.
Member of the SAB
M.D., Ph.D. Professor of Experimental Oncology, Karolinska Institutet Born: 1948
Rolf Kiessling is a professor of Experimental Oncology at Karolinska Institutet since 1995 and has a part-time position as Chief Physician at Radiumhemmet, Karolinska hospital. R.K. has published more than 200 publications in peer review journals and has broad scientific expertise in the field of experimental and clinical immunology. Among his earliest achievements, he discovered and named the NK- cell during the mid 70s, a discovery for which he was awarded “Anders Jahres medicinska pris for yngre forskare” 1985 and “Erik Fehrnströms pris” 1989. A more recent research focus of his group has been the area of immune therapy of cancer where his group is carrying out investigator initiated clinical trials on cancer patients and also performing basic research in pre-clinical animal models.
Inge Marie Svane
Member of SAB
M.D., Ph.D. Professor, Head of the Clinical Cancer Research Program, Faculty of Health Sciences, University of Copenhagen; Director, Centre for Cancer Immunotherapy (CCIT); consultant in Oncology, Herlev University Hospital
Inge Marie Svane, MD, PhD, joins Immunicum’s Scientific Advisory Board with 25 years of research experience in cancer immunology and immunotherapy. With her focus of expertise on T cell based adoptive cell therapy and other cellular therapies, cancer vaccines and immune regulation, she has greatly contributed to the field of cancer immunotherapy. Since 2001 she has initiated more than 20 Phase I and II immunotherapeutic trials as sponsor or principle investigator and has served as investigator and co-investigator on numerous international clinical trials in collaboration with the pharmaceutical industry, primarily within the area of cancer immunotherapy. Dr. Svane also led the establishment and currently serves as Director of the Centre for Cancer Immunotherapy (CCIT), Herlev University Hospital at the University of Copenhagen. Inge Marie has served as Chair of the European Society for Medical Oncology (ESMO) Scientific Committee on Immunotherapy and is author/co-author of more than 170 scientific publications including papers in Clinical Cancer Research, Cancer Research, Blood, Nature Immunology, Nature Biotechnology, Lancet Oncology, Immunology, Journal of Translational Medicine, PLOS ONE and Oncoimmunology, among others.
Member of the SAB
M.D., Ph.D. Vice Chair for Translational Research, Department of Medicine; Director of Cancer Vaccine and Dendritic Cell Therapies, Center for Immunotherapy; Professor of Oncology; and Co-Leader, Tumor Immunology & Immunotherapy (TII) CCSG Program, at Roswell Park Comprehensive Cancer Center
Pawel Kalinski is a distinguished MD/PhD researcher with over 30 years of experience in the field of tumor immunology. Dr. Kalinski’s research focuses on cell therapies and the manipulation of tumor microenvironments with a strong focus on the biology of dendritic cells, T cells and tumor microenvironment-associated myeloid cells. Currently, Pawel holds the positions of Vice Chair for Translational Research, Department of Medicine; Director of Cancer Vaccine and Dendritic Cell Therapies, Center for Immunotherapy; Professor of Oncology; and Co-Leader, Tumor Immunology & Immunotherapy (TII) CCSG Program, at Roswell Park Comprehensive Cancer Center in Buffalo, NY, USA. His research has been featured in over 120 international publications. Dr. Kalinski is also a member of several prestigious organizations including the Society for Immunotherapy of Cancer, American Association for Cancer Research, American Society for Clinical Investigation and the American Association of Immunologists and is a member of the editorial board of leading publications in the immuno-oncology field such as OncoImmunology and Journal for Immunotherapy of Cancer.